• Je něco špatně v tomto záznamu ?

Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy

L. Gorecki, M. Andrs, M. Rezacova, J. Korabecny

. 2020 ; 210 (-) : 107518. [pub] 20200226

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020528

Chemoresistance, radioresistance, and the challenge of achieving complete resection are major driving forces in the search for more robust and targeted anticancer therapies. Targeting the DNA damage response has recently attracted research interest, as these processes are enhanced in tumour cells. The major replication stress responder is ATM and Rad3-related (ATR) kinase, which is attracting attention worldwide with four drug candidates currently in phase I/II clinical trials. This review addresses a potent and selective small-molecule ATR inhibitor, which is known as VX-970 (also known as berzosertib or M6620), and summarizes the existing preclinical data to provide deep insight regarding its real potential. We also outline the transition from preclinical to clinical studies, as well as its relationships with other clinical candidates (AZD6738, VX-803 [M4344], and BAY1895344). The results suggest that VX-970 is indeed a promising anticancer drug that can be used both as monotherapy and in combination with either chemotherapy or radiotherapy strategies. Based on patient anamnesis and biomarker identification, VX-970 could become a valuable tool for oncologists in the fight against cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020528
003      
CZ-PrNML
005      
20210830102157.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pharmthera.2020.107518 $2 doi
035    __
$a (PubMed)32109490
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Gorecki, Lukas $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
245    10
$a Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy / $c L. Gorecki, M. Andrs, M. Rezacova, J. Korabecny
520    9_
$a Chemoresistance, radioresistance, and the challenge of achieving complete resection are major driving forces in the search for more robust and targeted anticancer therapies. Targeting the DNA damage response has recently attracted research interest, as these processes are enhanced in tumour cells. The major replication stress responder is ATM and Rad3-related (ATR) kinase, which is attracting attention worldwide with four drug candidates currently in phase I/II clinical trials. This review addresses a potent and selective small-molecule ATR inhibitor, which is known as VX-970 (also known as berzosertib or M6620), and summarizes the existing preclinical data to provide deep insight regarding its real potential. We also outline the transition from preclinical to clinical studies, as well as its relationships with other clinical candidates (AZD6738, VX-803 [M4344], and BAY1895344). The results suggest that VX-970 is indeed a promising anticancer drug that can be used both as monotherapy and in combination with either chemotherapy or radiotherapy strategies. Based on patient anamnesis and biomarker identification, VX-970 could become a valuable tool for oncologists in the fight against cancer.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a ATM protein $x antagonisté a inhibitory $x metabolismus $7 D064007
650    12
$a objevování léků $7 D055808
650    _2
$a synergismus léků $7 D004357
650    _2
$a lidé $7 D006801
650    _2
$a isoxazoly $x škodlivé účinky $x terapeutické užití $7 D007555
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a nádory $x farmakoterapie $x enzymologie $x patologie $7 D009369
650    _2
$a inhibitory proteinkinas $x škodlivé účinky $x terapeutické užití $7 D047428
650    _2
$a pyraziny $x škodlivé účinky $x terapeutické užití $7 D011719
650    _2
$a signální transdukce $7 D015398
650    _2
$a sulfony $x terapeutické užití $7 D013450
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Andrs, Martin $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic; Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic
700    1_
$a Rezacova, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 38 Hradec Kralove, Czech Republic
700    1_
$a Korabecny, Jan $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Electronic address: jan.korabecny@fnhk.cz
773    0_
$w MED00006662 $t Pharmacology & therapeutics $x 1879-016X $g Roč. 210, č. - (2020), s. 107518
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32109490 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102157 $b ABA008
999    __
$a ok $b bmc $g 1691158 $s 1140974
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 210 $c - $d 107518 $e 20200226 $i 1879-016X $m Pharmacology & therapeutics $n Pharmacol Ther $x MED00006662
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace